APT 2683

Drug Profile

APT 2683

Alternative Names: Malaria vaccine - Inflazyme

Latest Information Update: 25 Jan 2011

Price : $50

At a glance

  • Originator Inflazyme Pharmaceuticals
  • Class Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Malaria

Most Recent Events

  • 21 Apr 2004 Adprotech has been acquired by Inflazyme Pharmaceuticals
  • 08 Nov 2002 APT 2683 is available for licensing (http://www.adprotech.co.uk)
  • 29 Oct 2001 Preclinical development for Malaria in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top